STM Article Repository

Tan, Ying and Li, Ruihan and Zhou, Peipei and Li, Nan and Xu, Weilong and Zhou, Xiqiao and Yan, Qianhua and Yu, Jiangyi (2023) Huobahuagen tablet improves renal function in diabetic kidney disease: a real-world retrospective cohort study. Frontiers in Endocrinology, 14. ISSN 1664-2392

[thumbnail of pubmed-zip/versions/1/package-entries/fendo-14-1166880.pdf] Text
pubmed-zip/versions/1/package-entries/fendo-14-1166880.pdf - Published Version

Download (3MB)

Abstract

Objective: We aimed to explore the value of Huobahuagen tablet (HBT) in improving decreased renal function for patients with diabetic kidney disease (DKD) over time.

Methods: This was a single-center, retrospective, real-world study on eligible 122 DKD patients who continued to use HBT + Huangkui capsule (HKC) therapy or HKC therapy without interruption or alteration in Jiangsu Province Hospital of Chinese Medicine from July 2016 to March 2022. The primary observation outcomes included estimated glomerular filtration rate (eGFR) at baseline and 1-, 3-, 6-, 9-, and 12-month follow-up visits and changes in eGFR from baseline (ΔeGFR). Propensity score (PS) and inverse probability treatment weighting (IPTW) were used to control for confounders.

Results: eGFR was significantly higher in the HBT + HKC group than in the HKC alone group at the 6-, 9-, and 12-month follow-up visits (p = 0.0448, 0.0002, and 0.0037, respectively), indicating the superiority of HBT + HKC over HBT alone. Furthermore, the ΔeGFR of the HBT + HKC group was significantly higher than that of the HKC alone group at the 6- and 12-month follow-up visits (p = 0.0369 and 0.0267, respectively). In the DKD G4 patients, eGFR was higher in the HBT + HKC group at the 1-, 3-, 6-, 9-, and 12-month follow-up visits compared with baseline, with statistically significant differences at the 1-, 3-, and 6- month follow-up visits (p = 0.0256, 0.0069, and 0.0252, respectively). The fluctuations in ΔeGFR ranged from 2.54 ± 4.34 to 5.01 ± 5.55 ml/min/1.73 m2. Change in the urinary albumin/creatinine ratio from baseline did not exhibit a significant difference between the two groups at any of the follow-up visits (p > 0.05 for all). Adverse event incidence was low in both groups.

Conclusion: The findings of this study based on real-world clinical practice indicate that HBT + HKC therapy exhibited better efficacy in improving and protecting renal function with a favorable safety profile than HKC therapy alone. However, further large-scale prospective randomized controlled trials are warranted to confirm these results.

Item Type: Article
Subjects: GO for ARCHIVE > Mathematical Science
Depositing User: Unnamed user with email support@goforarchive.com
Date Deposited: 12 Oct 2023 06:50
Last Modified: 12 Oct 2023 06:50
URI: http://eprints.go4mailburst.com/id/eprint/996

Actions (login required)

View Item
View Item